Seres Therapeutics (NASDAQ: MCRB)
Seres Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Seres Therapeutics Company Info
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
News & Analysis
Why Shares of Seres Therapeutics Rose More Than 21% on Tuesday
The biotech stock announced it had enrolled its first patient in a trial for one of its therapies.
Why Shares of Seres Therapeutics Are Up More Than 22% Wednesday
Positive news for the company's lead therapy and improving financials helped push the stock.
Why Seres Therapeutics Stock Is Soaring Today
The company completed its target enrollment in a pivotal clinical study.
Why Seres Therapeutics Stock Is Crashing Today
The company reported disappointing results from a phase 2b clinical study.
Why Seres Therapeutics Stock Surged Today
A major investor boosted its stake in the microbiome therapeutics leader.
Why Seres Therapeutics Stock Skyrocketed 350% Today
The company's new drug could be a game changer.
Will the Gut Microbiome Change Medicine? Wall Street Isn't Convinced.
The potential is significant. Unfortunately, so is the hype.
Here's Why Seres Therapeutics Stock Soared Today
A new collaboration with AstraZeneca could give microbiome-based medicine a big lift.
Valuation
Earnings Transcripts
Seres Therapeutics Inc (MCRB) Q3 2020 Earnings Call Transcript
MCRB earnings call for the period ending September 30, 2020.
Seres Therapeutics Inc (MCRB) Q1 2020 Earnings Call Transcript
MCRB earnings call for the period ending March 31, 2020.
Seres Therapeutics Inc (MCRB) Q4 2019 Earnings Call Transcript
MCRB earnings call for the period ending December 31, 2019.
Seres Therapeutics Inc (MCRB) Q3 2019 Earnings Call Transcript
MCRB earnings call for the period ending September 30, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.